the bottom [500/mm:<50,000/mm 3 ) 1 Withhold dasatinib; may resume at original dosage (100 mg once daily) if ANC reaches 1000/mm 3 and platelets reach 50,000/mm 3 within 7 days 1 Second episode (ANC> <500/mm 3 lasting> 7 days or platelets <25,000/mm 3 ) 1 Withhold dasatinib; may resume at reduced dosage of 80 mg once daily when ANC reaches 1000/mm 3 and platelets reach 50,000/mm 3 1 Third episode (ANC> <500/mm 3 lasting> 7 days or platelets <25,000/mm 3 ) 1 Patients receiving dasatinib for newly diagnosed disease: Withhold dasatinib; may resume at reduced dosage of 50 mg once daily when ANC reaches 1000/mm 3 and platelets reach 50,000/mm 3 1 Patients receiving dasatinib following failure of prior therapy: Discontinue drug 1 Dosage Adjustments for Neutropenia and Thrombocytopenia: Accelerated Phase or Blast Phase CML and Ph+ ALL Initial Dosage Hematologic Measurements Dosage Adjustment 140 mg once daily 1 ANC> <500/mm 3 or platelets> <10,000/mm 3 1. If cytopenia is unrelated to leukemia (as determined by marrow aspirate or biopsy), discontinue dasatinib until ANC 1000/mm 3 and platelets 20,000/mm 3 1 2. Resume treatment at original dosage (140 mg once daily) 1 3. If recurrence of ANC> <500/mm 3 or platelets> <10,000/mm 3 occurs, repeat step 1 and resume therapy at a reduced dosage of 100 mg once daily (following a second episode) or 80 mg once daily (following a third episode) 1 4. If cytopenia is related to leukemia (as determined by marrow aspirate or biopsy), consider increasing dosage to 180 mg once daily 1 Special Populations Hepatic Impairment Dosage adjustment not necessary. 1 (See Hepatic Impairment under Cautions.) Renal Impairment No special dosage recommendations at this time. 1 (See Renal Impairment under Cautions.) Geriatric Patients No special dosage recommendations at this time. 1 (See Geriatric Use under Cautions.) Cautions for Dasatinib Contraindications No known contraindications. 1 Warnings/Precautions Fetal/Neonatal Morbidity and Mortality May cause fetal harm; teratogenicity and embryolethality demonstrated in animals. 1 Avoid pregnancy during therapy. 1 If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard. 1 Use adequate forms of contraception during therapy. 1 Women who are pregnant should not handle crushed or broken dasatinib tablets. 1 Hematologic Effects Myelosuppression (principally severe neutropenia, anemia, and thrombocytopenia) occurs commonly and is usually reversible; 1 more frequent in patients in the accelerated or blast phase of CML and in those with Ph + ALL than in patients in the chronic phase of CML. 1 Temporary suspension of therapy or dosage reduction may be required if hematologic toxicity occurs. 1 (See Dosage Modification for Toxicity under Dosage and Administration.) Perform CBCs weekly during the first 2 months of therapy and monthly (or as clinically indicated) thereafter. 1 Hemorrhage Risk of severe hemorrhage, including potentially fatal CNS or GI hemorrhage; usually associated with severe thrombocytopenia. 1 Severe GI hemorrhage may require treatment interruption and transfusions. 1 Use with caution in patients receiving anticoagulants or drugs that inhibit platelet function. 1 (See Specific Drugs under Interactions.) Fluid Retention Risk of potentially severe fluid retention (i.e., pleural effusion, pericardial effusion, pulmonary edema, ascites, generalized edema). 1 Fluid retention generally managed with supportive care (e.g., diuretics, short course of corticosteroids). 1 Evaluate symptoms suggestive of pleural effusion (e.g., dyspnea, dry cough) by chest radiograph. 1 Severe pleural effusion may require thoracentesis and oxygen therapy. 1 Hepatic Effects Grade 3 or 4 elevations of serum bilirubin, AST, and/or ALT reported; more frequent in patients in myeloid or lymphoid blast phase of CML and in those with Ph + ALL. 1 Electrolyte Disturbances Grade 3 or 4 hypophosphatemia and hypocalcemia reported; more frequent in patients in myeloid or lymphoid blast phase of CML and in those with Ph + ALL. 1 Hypocalcemia generally managed with oral calcium supplementation. 1 Prolongation of QT Interval May cause prolongation of the QT interval. 1 Use with caution in patients who have or may develop prolongation of the QT interval (e.g., hypokalemia, hypomagnesemia, congenital long QT syndrome, use of drugs known to prolong QT interval, cumulative high-dose anthracycline therapy). 1 Correct hypokalemia or hypomagnesemia prior to administration of dasatinib. 1 Left Ventricular Dysfunction, CHF, and MI Cardiomyopathy, CHF, diastolic dysfunction, fatal MI, and left ventricular dysfunction reported; monitor patient for manifestations of cardiac dysfunction and provide appropriate treatment if they occur. 1 Pulmonary Arterial Hypertension (PAH) May increase risk for development of PAH. 1 21 May occur at any time after initiation of therapy (e.g., 8 60 months); 1 21 22 23 24 25 reported most often in patients with comorbidities or receiving other drugs concomitantly. 21 May be reversible upon discontinuance of dasatinib. 1 21 22 23 24 Evaluate patient for manifestations of cardiopulmonary disease before and during dasatinib therapy. 1 21 Consider PAH in any patient with dyspnea, fatigue, hypoxia, and fluid retention; however, exclude other etiologies of dyspnea prior to initiating invasive diagnostic procedures for PAH. 1 21 Interruption of therapy accompanied by monitoring for improvement may be considered if PAH is suspected. 21 If PAH is confirmed (e.g., by cardiac catheterization), permanently discontinue the drug. 1 21 Lactose-intolerant Patients 140-mg daily dosage contains 189 mg of lactose monohydrate; 100-mg daily dosage contains 135 mg of lactose monohydrate. 1 Specific Populations Pregnancy Category D. 1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.) Lactation Not known whether dasatinib is distributed into milk. 1 Discontinue nursing because of potential risk to nursing infants. 1 10 Pediatric Use Safety and efficacy not established in patients> <18 years of age. 1 Geriatric Use No substantial difference in efficacy relative to younger adults, but patients 65 years of age are more likely to experience toxicity. 1 Hepatic Impairment Not studied in patients with hepatic impairment (ALT and/or AST> 2.5 times ULN 10 and/or total bilirubin >2 times ULN); however the drug is metabolized extensively in the liver. 1 10 Use with caution. 1 Renal Impairment Not studied in patients with renal impairment (S cr >1.5 times ULN); however, renal impairment not expected to decrease dasatinib clearance. 1 (See Special Populations under Pharmacokinetics.) Common Adverse Effects Patients receiving dasatinib as first-line therapy: Neutropenia, 1 thrombocytopenia, 1 anemia, 1 fluid retention (e.g., pleural effusion or superficial localized edema), 1 diarrhea, 1 headache, 1 musculoskeletal pain, 1 rash. 1 Patients receiving dasatinib following failure of prior therapy: Fluid retention (e.g., superficial and/or localized edema, generalized edema, pleural effusion, pericardial effusion, CHF or cardiac dysfunction, pulmonary edema), 1 2 neutropenia, 1 2 thrombocytopenia, 1 2 anemia, 1 hemorrhage (e.g., GI or CNS hemorrhage), 1 diarrhea, 1 2 vomiting, 1 2 abdominal pain, 1 nausea, 1 2 headache, 1 2 fatigue, 1 2 pyrexia, 1 musculoskeletal pain, 1 myalgia, 1 arthralgia, 1 rash, 1 2 dyspnea, 1 hypophosphatemia, 1 hypokalemia, 1 hypocalcemia, 1 febrile neutropenia, 1 infection (e.g., bacterial, viral, fungal). 1 2 Interactions for Dasatinib Metabolized principally by CYP3A4; weak inhibitor of CYP3A4. 1 Does not inhibit CYP isoenzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 2E1; does not induce human CYP isoenzymes. 1 Drugs Affecting Hepatic Microsomal Enzymes Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased plasma dasatinib concentrations). 1 Consider alternative drugs with no or less enzyme inhibition potential. 1 If concomitant use with a potent CYP3A4 inhibitor cannot be avoided, consider reducing dasatinib dosage to 20 mg daily (if current dosage is 100 mg daily) or to 40 mg daily (if current dosage is 140 mg daily) based on pharmacokinetic considerations (no clinical data with these dosage adjustments available). 1 If dasatinib is not tolerated following dosage reduction, discontinue the CYP3A4 inhibitor or interrupt dasatinib therapy until treatment with the CYP3A4 inhibitor is completed. 1 Upon discontinuance of a potent CYP3A4 inhibitor, allow approximately 1 week to elapse before increasing dasatinib dosage. 1 Inducers of CYP3A4: Potential pharmacokinetic interaction (decreased plasma dasatinib concentrations). 1 Avoid concomitant use of potent CYP3A4 inducers; consider alternative drugs with no or less enzyme induction potential. 1 If concomitant therapy cannot be avoided, consider increase in dasatinib dosage and closely monitor patient for toxicity. 1 Drugs Affecting Coagulation Potential for bleeding; use anticoagulants and drugs that inhibit platelet function concomitantly with caution. 1 Initial clinical trials of dasatinib excluded patients receiving such drugs; subsequent trials permitted use of anticoagulants, aspirin, and NSAIAs if patient's platelet count exceeded 50,000 75,000/mm 3 . 1 Drugs Metabolized by Hepatic Microsomal Enzymes Substrates of CYP3A4: Potential pharmacokinetic interaction (increased plasma substrate concentrations). 1 10 Specific Drugs and Foods Drug or Food Interaction Comments Alfentanil Possible increased plasma concentrations and AUC of alfentanil 1 Use concomitantly with caution 1 Antacids (e.g., calcium carbonate, aluminum and magnesium hydroxides) Possible decreased plasma dasatinib concentrations, secondary to apparent pH-dependence of dasatinib solubility 1 26 Dasatinib AUC unchanged when administered 2 hours after antacid (aluminum and magnesium hydroxides) but decreased 55% when administered concomitantly with antacid 1 26 Administer antacids 2 hours before or 2 hours after a dose of dasatinib 1 26 Anticoagulants (e.g., warfarin) Possible increased risk of hemorrhage 1 Use concomitantly with caution 1 Anticonvulsants (carbamazepine, phenobarbital, phenytoin) Possible decreased plasma dasatinib concentrations 1 Avoid concomitant use if possible; if concomitant therapy necessary, consider increasing dasatinib dosage and closely monitor for toxicity 1 Antifungals, azoles (i.e., itraconazole, ketoconazole, voriconazole) Possible increased plasma dasatinib concentrations and increased exposure to dasatinib 1 Ketoconazole: Increased dasatinib AUC by fivefold and peak concentration by fourfold 1 Avoid concomitant use if possible; if concomitant therapy necessary, closely monitor for toxicity and consider reducing dasatinib dosage to 20 mg daily (if current dosage is 100 mg daily) or 40 mg daily (if current dosage is 140 mg daily) 1 (see Drugs Affecting Hepatic Microsomal Enzymes under Interactions) Antihistamines (terfenadine and astemizole [no longer commercially available]) Possible increased plasma concentrations of terfenadine and astemizole 1 10 Cisapride Possible increased plasma concentrations of cisapride 1 10 Use concomitantly with caution 1 Dexamethasone Possible decreased plasma dasatinib concentrations 1 Avoid concomitant use if possible; if concomitant therapy necessary, consider increasing dasatinib dosage and closely monitor for toxicity 1 Ergot alkaloids (dihydroergotamine, ergotamine) Possible increased plasma concentrations of ergot alkaloids 1 10 Use concomitantly with caution 1 Fentanyl Possible increased plasma concentrations of fentanyl 1 10 Use concomitantly with caution 1 Grapefruit juice Possible increased plasma dasatinib concentrations 1 Avoid concomitant use 1 Histamine H 2 -receptor antagonists (e.g., cimetidine, famotidine, ranitidine) Possible decreased plasma dasatinib concentrations, secondary to apparent pH-dependence of dasatinib solubility 1 Famotidine: Decreased dasatinib AUC and peak concentration by 61 63% when given 10 hours before dasatinib 1 26 Concomitant use not recommended 1 HIV protease inhibitors (e.g., atazanavir, indinavir, nelfinavir, ritonavir, saquinavir) Possible increased plasma dasatinib concentrations and increased exposure to dasatinib 1 Avoid concomitant use if possible; if concomitant therapy necessary, closely monitor for toxicity and consider reducing dasatinib dosage to 20 mg daily (if current dosage is 100 mg daily) or 40 mg daily (if current dosage is 140 mg daily) 1 (see Drugs Affecting Hepatic Microsomal Enzymes under Interactions) Immunosuppressive agents (cyclosporine, sirolimus, tacrolimus) Possible increased plasma concentrations of immunosuppressive agents 1 10 Use concomitantly with caution 1 Macrolide antibiotics (i.e., clarithromycin, erythromycin, telithromycin) Possible increased plasma dasatinib concentrations and increased exposure to dasatinib 1 Avoid concomitant use if possible; if concomitant therapy necessary, closely monitor for toxicity and consider reducing dasatinib dosage to 20 mg daily (if current dosage is 100 mg daily) or 40 mg daily (if current dosage is 140 mg daily) 1 (see Drugs Affecting Hepatic Microsomal Enzymes under Interactions) Nefazodone Possible increased plasma dasatinib concentrations and increased exposure to dasatinib 1 Avoid concomitant use if possible; if concomitant therapy necessary, closely monitor for toxicity and consider reducing dasatinib dosage to 20 mg daily (if current dosage is 100 mg daily) or 40 mg daily (if current dosage is 140 mg daily) 1 (see Drugs Affecting Hepatic Microsomal Enzymes under Interactions) NSAIAs (e.g., aspirin) Possible increased risk of hemorrhage 1 Use concomitantly with caution 1 Pimozide Possible increased plasma concentrations of pimozide 1 10 Use concomitantly with caution 1 Proton-pump inhibitors (e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) Possible decreased plasma dasatinib concentrations, secondary to apparent pH-dependence of dasatinib solubility 1 Omeprazole: Decreased dasatinib AUC and peak concentration by 42 43% when given 22 hours before dasatinib 1 Concomitant use not recommended 1 Quinidine Possible increased plasma concentrations of quinidine 1 10 Use concomitantly with caution 1 Rifamycins (rifabutin, rifampin) Possible decreased plasma dasatinib concentrations and AUC of dasatinib 1 Rifampin: Decreased dasatinib AUC and peak concentration by 81 82% 1 Avoid concomitant use if possible; if concomitant therapy necessary, consider increasing dasatinib dosage and closely monitor for toxicity 1 St. John s wort ( Hypericum perforatum ) Potential for unpredictable decreases in plasma dasatinib concentrations 1 Concomitant use not recommended 1 Simvastatin Possible increased plasma concentrations and AUC of simvastatin 1 Use concomitantly with caution 1 Dasatinib Pharmacokinetics Absorption Onset Following oral administration, peak plasma concentrations are attained within 0.5 6 hours. 1 Special Populations In patients with moderate or severe hepatic impairment (Child-Pugh class B or C), peak plasma concentrations and AUC (normalized for differences in administered doses) are lower than in healthy individuals; differences not considered clinically important. 1 Distribution Extent Extensively distributed into the extravascular space. 1 Plasma Protein Binding Approximately 96 and 93% for dasatinib and active metabolite, respectively. 1 Elimination Metabolism Metabolized in the liver, principally by CYP3A4, to an active metabolite and several inactive metabolites. 1 Elimination Route Eliminated principally in feces (85%) mainly as metabolites and to a lesser extent in urine (4%). 1 Half-life 3 5 hours. 1 Special Populations No clinically relevant effects of age and gender on pharmacokinetics. 1 Stability Storage Oral Tablets 20 25 C (may be exposed to 15 30 C). 1 Actions Inhibits multiple tyrosine kinases including Bcr-Abl, the Src family (Src, Lck, Yes, Fyn), c-Kit, EphA-2, and platelet-derived growth factor (PDGFR)-β; predicted to bind to multiple conformations of the Abl kinase. 1 Inhibits Bcr-Abl tyrosine kinase, an abnormal protein created by the Philadelphia chromosome abnormality in CML and Ph + ALL that exhibits enhanced tyrosine kinase activity (i.e., increased phosphorylation of tyrosine residues). 5 6 7 8 9 Overcomes imatinib resistance resulting from Bcr-Abl kinase domain mutations, activation of alternate signaling pathways involving the Src family kinases (Lyn, Hck), and multidrug-resistance gene overexpression. 1 Advice to Patients Importance of taking only as prescribed. 1 Take at about the same time each day; do not discontinue therapy without first consulting clinician. 1 Importance of advising patients to swallow dasatinib tablets whole with water and not to break, chew, cut, or crush the tablets. 1 Importance of not drinking grapefruit juice while taking the drug. 1 Risk of severe fluid retention, bleeding, and cytopenia. 1 Importance of immediately informing clinician if fever, any bleeding or bruising, swelling, weight gain, or increasing shortness of breath occurs. 1 Importance of close medical supervision in patients receiving dasatinib. 1 Importance of informing clinicians if patient is lactose intolerant. 1 Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed; necessity for clinicians to advise women to avoid pregnancy during therapy, advise pregnant women of risk to the fetus, and advise women to utilize effective contraception during therapy. 1 Importance of advising patients that pregnant women should not handle crushed or broken dasatinib tablets. 1 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses. 1 Importance of informing patients of other important precautionary information. 1 (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Dasatinib Routes Dosage Forms Strengths Brand Names Manufacturer Oral Tablets, film-coated 20 mg Sprycel Bristol Myers-Squibb 50 mg Sprycel Bristol Myers-Squibb 70 mg Sprycel Bristol Myers-Squibb 80 mg Sprycel Bristol Myers-Squibb 100 mg Sprycel Bristol Myers-Squibb 140 mg Sprycel Bristol Myers Squibb AHFS DI Essentials. Copyright 2017, Selected Revisions August 13, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Bristol Myers-Squibb Company. Sprycel (dasatinib) tablets prescribing information and patient information. Princeton, NJ; 2011 Oct. 2. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med . 2006; 354:2531-41. [PubMed 16775234] 3. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program . 2005; :183-7. [PubMed 16304378] 4. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Rockville, MD; 2006 Mar 21. From FDA website. Accessed 2011 Oct 31. 5. Druker BJ, Lydon NB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Investig . 2000; 105:3-7. [PubMed 10619854] 6. McGuire TR, Kazakoff PW. Chronic leukemias. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford: Appleton and Lange; 1999:2169-80. 7. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med . 2001; 344:1031-7. [PubMed 11287972] 8. Anon. Gleevec (STI-571) for chronic myeloid leukemia. Med Lett Drugs Ther . 2001; 43:49-50. [PubMed 11402258] 9. Weisberg E, Griffin J. Mechanisms of resistance imatinib (STI-571) in preclinical models and in leukemia patients. Drug Resistance Updates . 2001; 4:22-8. [PubMed 11512149] 10. Bristol-Myers Squibb, Plainsboro, NJ: Personal communication. 11. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol . 2008; 26:3204-12. [PubMed 18541900] 12. Kantarjian H, Cortes J, Kim DW et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood . 2009; 113:6322-9. [PubMed 19369231] 13. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood . 2007; 109:5143-50. [PubMed 17317857] 14. Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chcronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia . 2008; 22:1200-6. [PubMed 18401416] 15. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood . 2007; 110:2309-15. [PubMed 17496201] 16. Cortes J, Kim DW, Raffoux E et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia . 2008; 22:2176-83. [PubMed 18754032] 17. Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood . 2007; 109:4143-50. [PubMed 17264298] 18. Food and Drug Administration. Center for Drug Evaluation and Research: Application number 21-986 and 22-072: Medical Review(s). From FDA website. 19. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med . 2010; 362:2260-70. [PubMed 20525995] 20. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst . 1998; 90:850-8. [PubMed 9625174] 21. Food and Drug Administration. Drug safety communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension [Oct 2011]. From FDA web site. 22. Mattei D, Feola M, Orzan F et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant . 2009; 43:967-8. [PubMed 19104491] 23. Dumitrescu D, Seck C, ten Freyhaus H et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J . 2011; 38:218-20. [PubMed 21719499] 24. Orlandi EM, Rocca B, Pazzano AS et al. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res . 2011; :. [PubMed 21890201] 25. . Dasatinib: pulmonary arterial hypertension. French data. Prescrire Int . 2011; 20:241. 26. Eley T, Luo FR, Agrawal S et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol . 2009; 49:700-9. [PubMed 19395585] Next Interactions Print this page Add to My Med List More about dasatinib Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 17 Reviews Add your own review/rating Drug class: BCR-ABL tyrosine kinase inhibitors Consumer resources Dasatinib Dasatinib (Advanced Reading) Professional resources Dasatinib (Wolters Kluwer) Other brands: Sprycel Related treatment guides Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Leukemia ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only D Pregnancy Category Positive evidence of risk N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class BCR-ABL tyrosine kinase inhibitors Related Drugs Chronic Myelogenous Leukemia hydroxyurea , Hydrea , Gleevec , cyclophosphamide , imatinib , Sprycel , Tasigna , cytarabine , More... Acute Lymphoblastic Leukemia methotrexate , Gleevec , mercaptopurine , imatinib , Adriamycin , doxorubicin , Sprycel , More... Leukemia prednisone , triamcinolone , dexamethasone , Decadron , Deltasone , Sprycel , Kenalog-40 , More... Dasatinib Rating 17 User Reviews 8.6 /10 17 User Reviews 8.6 Rate it!} } income
labeled Dasatinib of moral
EmoticonEmoticon